Patent · US Active

Anti-CD16 binding molecules

US9701750B2 · kind B2 · utility

4Cited by

8References

16Claims

0Family size

Assignee

AFFIMED GMBH · DE

Inventors

Karin Hoffmann · Schwetzingen, DE
Sergey Kipriyanov · Heidelberg, DE
Stefan Knackmuss · Plankstadt, DE
Fabrice Le Gall · Mainz, DE
Melvyn Little · Büdelsdorf, DE
Uwe Reusch · Maikammer, DE

Key dates

Filing date	Apr 20, 2015
Grant date	Jul 11, 2017
Priority date	—
Expiry date	Apr 20, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of FcγRIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.